Extrapulmonary small cell carcinoma is very rare. Its prognosis is poor and there is no established treatment modality. It has been considered as a distinct clinicopathological entity. It is distinct from small cell carcinoma of the lung, though it shares similar clinicopathologic features to the latter. It has a similar staging and treatment modality. The aim is to review existing studies and provide new results on diagnosis and current management strategy for patients with Extrapulmonary small cell carcinoma. The study involves the review of the literature using the electronic database MEDLINE and hand searching of journals. The outcome measures are addressed and analyzed. Studies have shown wide variations of treatment modalities adopted and the outcome observed. Almost all studies are of inadequate power to establish standard treatment modality. Multi-centre studies are required to institutionalize standard treatment modality.
INTRODUCTION

DISCUSSION
Undifferentiated small cell carcinoma (SCC) is an aggressive lung tumour accounting for 15% of all lung cancers. 1 Extrapulmonary small cell carcinomas (ESCs) are uncommon malignant neoplasms with a reported incidence of 0.1 to 0.4% of all cancers. system hypothesis which proposes a common ancestral cell derived from the neural crest. 26 Histopathological diagnosis can be made by its classic appearance of small round to oval shaped cells with a finely granular and hyperchromatic nucleus, inconspicuous nucleoli and scanty cytoplasm on light microscopy. 27 The percentages of SCC samples with positive mg /m2 and all are given intravenously on days 1 to 3 for every three weeks for 3 to 6 cycles. Topotecan (0.75mg/m2) combined with standard PE regimen for patients with ED-SCLC was failed to provide any benefit in terms of response and survival in patients of this group. 33 The clinical benefit of second-line therapy for relapsed small cell lung carcinoma is also limited. 34 However, a long survival time is observed by using combination chemotherapy with tegafur/ gimeracil/oteracil potassium + cisplatin and irinotecan hydrochloride + cisplatin after gastrectomy. 
